Skip to main content

Table 2 Genes responsive to LPS that do not contain putative κB in their upstream sequences

From: Transcriptional profiling of the LPS induced NF-κB response in macrophages

Accession No

Symbol

Gene Name

Chemokines and receptors

[genebank:NM_021006]

CCL3L1

Chemokine, CC motif, ligand 3-like protein 1 π #

[genebank:NM_002988]

CCL18

Chemokine, CC motif, ligand 18

[genebank:NM_005623]

CCL8

Chemokine, CC motif, ligand 8 π #

[genebank:NM_002991]

CCL24

Chemokine, CC motif, ligand 24 #

[genebank:NM_001838]

CCR7

Chemokine, CC motif, receptor 7 #

[genebank:NM_002620]

PF4V1

Platlet Factor 4, variant 1

Angiogenesis

[genebank:NM_003246]

THBS1

Thrombospondin 1 #

[genebank:NM_012484]

HMMR

Hyaluronan-mediated motility receptor #

Cytokines and Receptors

  

[genebank:NM_003853]

IL18 RAP

Interleukin 18 receptor accessory protein #

[genebank:NM_000565]

IL6R

Interleukin 6 receptor #

Apoptosis

[genebank:U75285]

AIP4

Apoptosis inhibitor 4 (survivin)

[genebank:NM_021127]

PMAIP1

Phorbol 12 myristate 13 acetate induced protein 1 *#

[genebank:NM_014456]

PDC4

Programmed cell death 4 π

[genebank:X75252]

PBP

Prostatic binding protein #

Transcription

[genebank:NM_001211]

BUB1β

Budding uninhibited by benzimidazoles 1, S. Cerevisiae homolog of B π#

[genebank:X52317]

H2FAZ

H2A histone family member Z

[genebank:NM_002128]

HMGB1

High mobility group box 1

[genebank:NM_006618]

JARID1B

Jumonji, AT-rich interactive domain 1B π #

[genebank:NM_006347]

PPIH

Peptidyl-prolyl isomerase H #

[genebank:NM_005030]

PLK1

Polo-like kinase #

[genebank:NM_001067]

TOP2a

Topoisomerase, DNA, 11, α π

Growth

[genebank:NM_000222]

KIT

v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog

Miscellaneous

[genebank:NM_019111]

HLADRα

Major histocompatibilty complex, class II, DR α π

[genebank:D14657]

 

K1AA0247 #

[genebank:NM_006062]

SMYD5

SMYD family member 5 π

  1. π Indicates those genes validated using real time PCR. # Indicates those genes that contain putative IRF-3 sites [see Additional file 1 for position].